CGEN - Compugen Ltd.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
3.40
+0.05 (+1.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.35
Open3.40
Bid2.00 x 200
Ask3.60 x 1500
Day's Range3.40 - 3.45
52 Week Range2.25 - 5.40
Volume147,863
Avg. Volume235,370
Market Cap173.89M
Beta2.39
PE Ratio (TTM)N/A
EPS (TTM)-0.72
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.10
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018, at 10:00 AM Eastern Time. ...

  • Associated Press4 days ago

    Compugen reports 4Q loss

    The Holon, Israel-based company said it had a loss of 18 cents per share. For the year, the company reported that its loss widened to $37.1 million, or 72 cents per share. The company's shares closed at ...

  • PR Newswire4 days ago

    Compugen Reports Fourth Quarter and Full Year 2017 Results

    Phase 1 Trial for COM701 Expected to Start in 2018 Bayer in Late Stage Preclinical Development of CGEN-15001T Program HOLON, Israel , Feb. 21, 2018 /PRNewswire/ -- Compugen Ltd. ( NASDAQ: CGEN ), a leader ...

  • ACCESSWIRE17 days ago

    Wired News – Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases

    Stock Monitor: Array BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN ). If you ...

  • PR Newswire17 days ago

    Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET

    HOLON, Israel , Feb. 8, 2017  /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

  • PR Newswire19 days ago

    Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology

    HOLON, Israel, Feb. 6, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the online publication of the discovery and validation of the ILDR2 protein as a novel immune checkpoint and its use as an Fc fusion protein for the treatment of autoimmune diseases in two peer-reviewed papers in The Journal of Immunology. Antibody-based therapeutics targeting ILDR2, designated by Compugen as CGEN-15001T, for immuno-oncology were licensed to Bayer, while Compugen retains the full rights to the fusion protein, designated as CGEN-15001, consisting of the extracellular domain of ILDR2 and an Fc domain, for potential use in autoimmune diseases.

  • PR Newswirelast month

    Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors

    HOLON, Israel, Jan. 18, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced new preclinical data demonstrating distinctive features of the PVRIG pathway and the potential of COM701, a first-in-class therapeutic antibody candidate targeting PVRIG, for treating multiple solid tumors. The data, presented at the Keystone Symposia Conference, A3: T Cell Dysfunction, Cancer and Infection, being held January 16-20, 2018, at the Beaver Run Resort, Breckenridge, CO, provide indication for a dominant role of the PVRIG/TIGIT axis in cancer evasion of immune response in multiple cancers.

  • PR Newswire2 months ago

    Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences

    HOLON, Israel , January 2, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced upcoming ...

  • What You Must Know About Compugen Ltd’s (NASDAQ:CGEN) Financial Health
    Simply Wall St.2 months ago

    What You Must Know About Compugen Ltd’s (NASDAQ:CGEN) Financial Health

    Compugen Ltd (NASDAQ:CGEN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CGEN willRead More...

  • How Compugen Ltd’s (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too?
    Simply Wall St.3 months ago

    How Compugen Ltd’s (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too?

    After looking at Compugen Ltd’s (NASDAQ:CGEN) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • Is It Too Late To Buy Compugen Ltd (CGEN)?
    Simply Wall St.3 months ago

    Is It Too Late To Buy Compugen Ltd (CGEN)?

    Compugen Ltd (NASDAQ:CGEN), a life sciences tools and services company based in Israel, received a lot of attention from a substantial price movement on the NasdaqGM in the over theRead More...

  • ACCESSWIRE4 months ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 10:00 AM Eastern Time. ...

  • Associated Press4 months ago

    Compugen reports 3Q loss

    On a per-share basis, the Holon, Israel-based company said it had a loss of 19 cents. The company's shares closed at $3. A year ago, they were trading at $5.95. _____ This story was generated by Automated ...

  • PR Newswire4 months ago

    Compugen Reports Third Quarter 2017 Results

    - Phase I Study for COM701 Expected to Start in 2018 - IND Application for COM902 Anticipated in 2019 HOLON, Israel , Nov. 7, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery ...

  • TheStreet.com4 months ago

    Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

    The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

  • PR Newswire4 months ago

    Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with Mount Sinai, under the direction of Miriam Merad, MD, PhD, Director of the Precision Immunology Institute and Co-Leader of the Cancer Immunology program and Mount Sinai Professor in Cancer Immunology at the Icahn School of Medicine at Mount Sinai in New York. Dr. Merad is a world-class leader in the field of myeloid biology for the development of novel cancer immunotherapies and is a member of Compugen's Scientific Advisory Board (SAB).

  • PR Newswire4 months ago

    Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it will present two posters with new data on COM701, the Company's first-in class immuno-oncology therapeutic antibody candidate targeting PVRIG, and COM902, the Company's immuno-oncology therapeutic antibody targeting TIGIT, at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8-12 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "Analysis of the TIGIT/PVRIG axis in human cancers to support indication selection and biomarkers for COM701 and COM902" (Poster no. P369) will be presented on Friday, November 10, 2017 at 12:30-2 pm and 6:30-8 pm ET.

  • PR Newswire4 months ago

    Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its third quarter financial results on Tuesday, November 7, 2017 before the U.S. financial markets open. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

  • ACCESSWIRE5 months ago

    Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032

    LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Compugen Ltd (NASDAQ: CGEN ), following which we have published ...

  • Company News For Oct 10, 2017
    Zacks5 months ago

    Company News For Oct 10, 2017

    Companies in the news are: MZOR,CGEN,KTWO,AXTA

  • TheStreet.com5 months ago

    Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

    Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

  • PR Newswire5 months ago

    A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy

    HOLON, Israel, Oct. 9, 2017 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, disclosed new data demonstrating the potential of CGEN-15032 as a target for the development of first-in-class cancer therapy. CGEN-15032 is a novel myeloid and epithelial immuno-oncology target, which may serve as an immuno-suppressive target within the tumor microenvironment.

  • Compugen Ltd (CGEN): How Does It Impact Your Portfolio?
    Simply Wall St.5 months ago

    Compugen Ltd (CGEN): How Does It Impact Your Portfolio?

    If you are looking to invest in Compugen Ltd’s (NASDAQ:CGEN), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • PR Newswire7 months ago

    Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month

    Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology target, will be the subject of both an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference taking place September 6-9, 2017 in Mainz/Frankfurt, Germany. The presentation titled "Computational discovery and experimental validation of CGEN-15032 as a novel target for cancer immunotherapy" is scheduled as part of the session titled "Other checkpoint blocking and immunomodulating antibodies," on Friday, September 8, 2:00-3:45 pm CEST.

  • ACCESSWIRE7 months ago

    Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen

    Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...